Trial Outcomes & Findings for Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) (NCT NCT00535743)

Last Updated: 2019-02-11

Results Overview

Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units "minutes:seconds" (mm:ss), was reformatted to be presented in the single unit of "minutes" (min).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

174 participants

Primary outcome timeframe

Up to 240 minutes following administration of study treatment

Results posted on

2019-02-11

Participant Flow

Of the N=174 randomized participants, N=173 received treatment. Treated participants are counted as Started in the arm that most accurately describes the treatment received. If no treatment was received (N=1 participant), participants are counted as Started in the arm to which they were randomized.

N=2 participants (randomized to Arm O) received (rec'd) 8 mg/kg Sugammadex, 3 minutes (min) after 1.2 mg/kg Esmeron® and are counted as Started/Treated in Arm P. Further, N=1 participant (randomized to Arm Q) rec'd 12 mg/kg Sugammadex, 29 min after 1.2 mg/kg Esmeron® and is counted as Started/Treated in Arm W.

Participant milestones

Participant milestones
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron® Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron® Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron® Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron® Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Overall Study STARTED	5	11	11	11	11	10	3	5	5	5	5	5	5	10	9	13	10	11	3	5	5	5	6	5
Overall Study Treated	5	11	11	11	11	10	3	5	4	5	5	5	5	10	9	13	10	11	3	5	5	5	6	5
Overall Study COMPLETED	5	11	11	11	11	10	3	5	4	4	5	5	5	10	9	13	10	11	3	5	5	4	6	5
Overall Study NOT COMPLETED	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron® n=5 Participants Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=10 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=4 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron® n=5 Participants Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=9 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=13 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=6 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Total n=173 Participants Total of all reporting groups
Age, Continuous	49.8 Years STANDARD_DEVIATION 16.0 • n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	45.8 Years STANDARD_DEVIATION 17.9 • n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	48.4 Years STANDARD_DEVIATION 16.3 • n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	46.8 Years STANDARD_DEVIATION 11.3 • n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	47.5 Years STANDARD_DEVIATION 12.8 • n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	54.9 Years STANDARD_DEVIATION 17.5 • n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	43.3 Years STANDARD_DEVIATION 5.7 • n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	51.2 Years STANDARD_DEVIATION 18.9 • n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	63.0 Years STANDARD_DEVIATION 6.2 • n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	45.2 Years STANDARD_DEVIATION 17.3 • n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	56.0 Years STANDARD_DEVIATION 8.9 • n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	62.4 Years STANDARD_DEVIATION 7.9 • n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	57.2 Years STANDARD_DEVIATION 13.2 • n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	53.0 Years STANDARD_DEVIATION 16.2 • n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	47.9 Years STANDARD_DEVIATION 21.1 • n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	52.6 Years STANDARD_DEVIATION 12.6 • n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	57.5 Years STANDARD_DEVIATION 14.6 • n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	48.7 Years STANDARD_DEVIATION 15.4 • n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	48.0 Years STANDARD_DEVIATION 28.0 • n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	41.8 Years STANDARD_DEVIATION 21.3 • n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	45.0 Years STANDARD_DEVIATION 17.0 • n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	44.8 Years STANDARD_DEVIATION 19.8 • n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	51.8 Years STANDARD_DEVIATION 10.3 • n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	46.0 Years STANDARD_DEVIATION 22.4 • n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	50.4 Years STANDARD_DEVIATION 15.6 • n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Sex: Female, Male Female	2 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	2 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	6 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	6 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	6 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	2 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	2 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	80 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Sex: Female, Male Male	3 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	8 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	6 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	6 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	93 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) Asian	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) White	5 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	4 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	13 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	3 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	5 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	171 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) More than one race	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=7 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=5 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=4 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=21 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=8 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=42 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=36 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=24 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=135 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=136 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=44 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=667 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	1 Participants n=12 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0 Participants n=11 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	2 Participants n=6 Participants • Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).

PRIMARY outcome

Timeframe: Up to 240 minutes following administration of study treatment

Population: Includes all participants receiving study treatment, having ≥1 post-baseline observation without a major protocol violation. Additionally, N=1 participant was excluded from Arm M due to missing data and N=1 participant was excluded from Arm N due to unreliability of the neuromuscular data.

Outcome measures

Outcome measures
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron® n=5 Participants Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=10 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=4 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron® n=4 Participants Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=9 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=8 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9	108.43 minutes Standard Deviation 31.17	44.73 minutes Standard Deviation 22.18	6.93 minutes Standard Deviation 2.87	2.40 minutes Standard Deviation 1.17	2.42 minutes Standard Deviation 2.12	1.77 minutes Standard Deviation 1.13	127.37 minutes Standard Deviation 92.77	8.53 minutes Standard Deviation 1.12	5.47 minutes Standard Deviation 3.13	1.85 minutes Standard Deviation 0.55	1.78 minutes Standard Deviation 0.87	0.93 minutes Standard Deviation 0.13	122.98 minutes Standard Deviation 28.47	65.67 minutes Standard Deviation 24.58	13.78 minutes Standard Deviation 7.63	3.23 minutes Standard Deviation 0.98	2.08 minutes Standard Deviation 0.85	1.32 minutes Standard Deviation 0.42	139.62 minutes Standard Deviation 79.88	42.20 minutes Standard Deviation 29.33	5.97 minutes Standard Deviation 2.47	2.33 minutes Standard Deviation 0.30	1.77 minutes Standard Deviation 1.18	4.73 minutes Standard Deviation 6.68

SECONDARY outcome

Timeframe: Up to 200 minutes following administration of study treatment

Population: Includes all participants receiving study treatment, having ≥1 post-baseline observation without a major protocol violation.

Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.8 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of NMB present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.8 indicates faster recovery from NMB. Summary data, originally presented in the format of units "minutes:seconds" (mm:ss), was reformatted to be presented in the single unit of "minutes" (min).

Outcome measures

Outcome measures
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron® n=5 Participants Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=10 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=4 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron® n=5 Participants Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=8 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.8	98.23 minutes Standard Deviation 28.82	40.00 minutes Standard Deviation 20.47	5.90 minutes Standard Deviation 2.40	1.87 minutes Standard Deviation 0.73	1.57 minutes Standard Deviation 1.35	1.43 minutes Standard Deviation 0.97	91.53 minutes Standard Deviation 43.73	6.23 minutes Standard Deviation 1.23	4.10 minutes Standard Deviation 2.60	1.45 minutes Standard Deviation 0.43	1.33 minutes Standard Deviation 0.50	0.93 minutes Standard Deviation 0.13	129.85 minutes Standard Deviation 39.48	60.85 minutes Standard Deviation 21.13	8.52 minutes Standard Deviation 2.80	2.80 minutes Standard Deviation 1.02	1.73 minutes Standard Deviation 0.82	1.20 minutes Standard Deviation 0.27	121.03 minutes Standard Deviation 63.07	33.95 minutes Standard Deviation 23.02	4.42 minutes Standard Deviation 1.38	1.98 minutes Standard Deviation 0.27	1.72 minutes Standard Deviation 1.07	1.27 minutes Standard Deviation 0.60

SECONDARY outcome

Timeframe: Up to 180 minutes following administration of study treatment

Population: Includes all participants receiving study treatment, having ≥1 post-baseline observation without a major protocol violation.

Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.7 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of NMB present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.7 indicates faster recovery from NMB. Summary data, originally presented in the format of units "minutes:seconds" (mm:ss), was reformatted to be presented in the single unit of "minutes" (min).

Outcome measures

Outcome measures
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron® n=5 Participants Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=10 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=4 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron® n=5 Participants Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=8 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.7	91.58 minutes Standard Deviation 27.43	36.43 minutes Standard Deviation 17.22	4.55 minutes Standard Deviation 1.43	1.58 minutes Standard Deviation 0.70	1.13 minutes Standard Deviation 0.12	1.27 minutes Standard Deviation 0.52	81.70 minutes Standard Deviation 34.18	5.28 minutes Standard Deviation 0.77	3.28 minutes Standard Deviation 1.62	1.25 minutes Standard Deviation 0.15	1.28 minutes Standard Deviation 0.42	0.93 minutes Standard Deviation 0.13	122.90 minutes Standard Deviation 36.23	54.43 minutes Standard Deviation 17.33	7.45 minutes Standard Deviation 2.82	2.42 minutes Standard Deviation 0.85	1.62 minutes Standard Deviation 0.80	1.18 minutes Standard Deviation 0.22	111.37 minutes Standard Deviation 53.03	24.15 minutes Standard Deviation 13.00	3.08 minutes Standard Deviation 0.90	1.58 minutes Standard Deviation 0.35	1.67 minutes Standard Deviation 0.97	1.22 minutes Standard Deviation 0.57

SECONDARY outcome

Timeframe: Up to 7 days following administration of study treatment

Population: Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).

The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.

Outcome measures

Outcome measures
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron® n=5 Participants Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=11 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron® n=10 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=4 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron® n=5 Participants Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=9 Participants Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=13 Participants Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=10 Participants Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron® n=11 Participants Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron® n=3 Participants Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=6 Participants Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron® n=5 Participants Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Number of Participants Experiencing an Adverse Event	5 Participants	5 Participants	7 Participants	7 Participants	8 Participants	7 Participants	2 Participants	4 Participants	3 Participants	4 Participants	3 Participants	4 Participants	3 Participants	5 Participants	7 Participants	5 Participants	6 Participants	9 Participants	3 Participants	2 Participants	4 Participants	1 Participants	3 Participants	3 Participants

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron n=5 participants at risk Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=10 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron n=3 participants at risk Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=4 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron n=5 participants at risk Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=10 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=9 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=13 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=10 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=11 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron n=3 participants at risk Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=6 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Cardiac disorders Cardiac arrest	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Abdominal pain	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Post procedural haemorrhage	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Investigations Electrocardiogram QT corrected interval prolonged	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	30.0% 3/10 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	22.2% 2/9 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).

Other adverse events

Other adverse events
Measure	Arm A. Placebo; 3 Min After 1 mg/kg Esmeron n=5 participants at risk Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm B. 2 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm C. 4 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm D. 8 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm E. 12 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=11 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm F. 16 mg/kg Sugammadex; 3 Min After 1 mg/kg Esmeron n=10 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm G. Placebo; 15 Min After 1 mg/kg Esmeron n=3 participants at risk Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm H. 2 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm I. 4 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=4 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm J. 8 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm K. 12 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm L. 16 mg/kg Sugammadex; 15 Min After 1 mg/kg Esmeron n=5 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.	Arm M. Placebo; 3 Min After 1.2 mg/kg Esmeron n=5 participants at risk Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm N. 2 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=10 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm O. 4 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=9 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm P. 8 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=13 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm Q. 12 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=10 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm R. 16 mg/kg Sugammadex; 3 Min After 1.2 mg/kg Esmeron n=11 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm S. Placebo; 15 Min After 1.2 mg/kg Esmeron n=3 participants at risk Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm T. 2 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm U. 4 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm V. 8 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm W. 12 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=6 participants at risk Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.	Arm X. 16 mg/kg Sugammadex; 15 Min After 1.2 mg/kg Esmeron n=5 participants at risk Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
Cardiac disorders Bradycardia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Ear and labyrinth disorders Vertigo	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	22.2% 2/9 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Eye disorders Eye irritation	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Constipation	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Dry mouth	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Dyspepsia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Nausea	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	27.3% 3/11 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	27.3% 3/11 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	25.0% 1/4 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	44.4% 4/9 • Number of events 4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	40.0% 2/5 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Toothache	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
General disorders Malaise	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Gastrointestinal disorders Vomiting	40.0% 2/5 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	27.3% 3/11 • Number of events 4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	40.0% 4/10 • Number of events 4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	40.0% 2/5 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	100.0% 3/3 • Number of events 4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
General disorders Chills	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
General disorders Infusion site erythema	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Anaesthetic complication	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	36.4% 4/11 • Number of events 4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	75.0% 3/4 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	40.0% 2/5 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	15.4% 2/13 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 2/10 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	45.5% 5/11 • Number of events 7 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
General disorders Pain	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 2/10 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	30.0% 3/10 • Number of events 3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	22.2% 2/9 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 2/10 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	16.7% 1/6 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Airway complication of anaesthesia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Vascular disorders Hypotension	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	16.7% 1/6 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Delayed recovery from anaesthesia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Periorbital haematoma	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Post procedural haematoma	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Post procedural haemorrhage	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	16.7% 1/6 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Post procedural pain	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Procedural hypertension	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Injury, poisoning and procedural complications Procedural hypotension	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	25.0% 1/4 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	18.2% 2/11 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Investigations Blood pressure increased	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Investigations Haemoglobin decreased	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Investigations Heart rate decreased	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Investigations Red blood cell count decreased	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Psychiatric disorders Agitation	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Nervous system disorders Dizziness	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Nervous system disorders Headache	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Nervous system disorders Paraesthesia	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Psychiatric disorders Restlessness	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Renal and urinary disorders Oliguria	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Respiratory, thoracic and mediastinal disorders Cough	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Respiratory, thoracic and mediastinal disorders Pharyngolaryngeal pain	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Skin and subcutaneous tissue disorders Swelling face	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Vascular disorders Haematoma	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Vascular disorders Haemorrhage	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Vascular disorders Hot flush	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/9 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/13 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/6 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).
Vascular disorders Hypertension	40.0% 2/5 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/11 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/3 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/4 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	20.0% 1/5 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/10 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	11.1% 1/9 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	7.7% 1/13 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	10.0% 1/10 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	9.1% 1/11 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	33.3% 1/3 • Number of events 1 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	16.7% 1/6 • Number of events 2 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).	0.00% 0/5 • Up to 7 days following administration of study treatment Includes all participants receiving study treatment. N=2 participants (originally randomized to Arm O), rec'd 8 mg/kg sugammadex, 3 min after 1.2 mg/kg Esmeron® (counted in Arm P). N=1 participant (originally randomized to Arm Q) rec'd 12 mg/kg sugammadex, 29min after 1.2 mg/kg Esmeron® (counted in Arm W).

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor recognizes the right of the investigators to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.
Publication restrictions are in place

Restriction type: OTHER